Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

AACR 2022 | Ulixertinib in tumors with BRAF fusions, non-V600E or non-V600K BRAF mutations

Vivek Subbiah, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a subset of results from the phase II MATCH trial (NCT02465060), evaluating genetically-directed treatments in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment. The sub-protocol looked at ulixertinib, an ERK 1/2 kinase inhibitor, in BRAF non-V600 mutation, BRAF fusion, or other BRAF aberrations across multiple cancers in a tissue agnostic manner. In the absence of specific BRAF V600E inhibitors, ERK inhibitors have shown early signals of activity across multiple tumor types in preclinical and early phase I studies. Twenty late-line patients were enrolled based on molecular analysis of cytologic samples and it was found that ulixertinib did not have significant activity in this cohort. Future directions for this study involve returning to the preclinical model to identify potential adaptive mechanisms of resistance and to identify possible combination therapies to improve the response rate. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.